QuickView for release of matrix enzymes from mitochondria (biogroup)

1. NSCLC PC9 cells selected for gefitinib sensitivity or resistance treated with EGF and gefitinib
2. Limited systemic sclerosis patients with and without pulmonary arterial hypertension (PAH)
3. L1000 CMAP Liver cancer HEP G2 cells with gene overexpression perturbations
4. L1000 CMAP Osteosarcoma U-2 OS cells with gene overexpression perturbations
5. Programming human pluripotent stem cells into adipocytes

There were no matches for release of matrix enzymes from mitochondria

1. Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Neph…
2. The KHENEREXT Study